Just filed IIJIN sold a pant load of stock in January leading up to the 22nd. They left a lot in the table..

S&P puts Big Oil names on negative watch due to climate risk
https://seekingalpha.com/news/3654459-sp-puts-big-oil-names-on-negative-watch-due-to-climate-risk

Thought this would happen at the end of the year.

I expect Mackie Research is attempting to support a client that was short Aurinia..

Another new 52 week high, $19.46

Mr o, FANG. One of the lowest cost producers in the US. They will be left standing no matter what..

They don’t like this

Now, you know that was all in jest, right?

One thing for sure, the price of the commodity is heading higher. I just read a piece were China’s drilling activity has dropped quite a bit. Best bet in my book is Diamond.

I fear the $22’s if I’m not on board!

I’ve sent them an invite. It does expire and block their access forever once AUPH reaches $50 per share, pre-split.

What a gift. I never thought I could buy more this morning in the $17’s

President Biden is said to be planning several orders on climate change, including a move toward banning new oil and gas drilling on federal land.
Monday, January 25, 2021 6:03 PM EST
An eventual ban on new drilling permits would fulfill a campaign promise that infuriated the oil industry and became a central theme in the fight for the critical battleground state of Pennsylvania, where the natural gas extraction method known as hydraulic fracturing, or fracking, has become big business.

I expect he is moving a little too fast, which could result in unintended consequences..

Getting the reversal off the bottom of the range..

To continue the thread, this was from a Barron’s piece from the middle of December:

“Tesla’s addition to the S&P 500 followed its reporting of a requisite four consecutive profitable quarters, which can be “traced entirely to energy credit sales plus noncash account and unusual items—none of which are its core business,” she writes.”

Undercurrents are not good..

Jess, you are spot on. This is last call for anyone short.

We are heading to the $16’s for a short period. This is Adam F’s recent post:

$AUPH — Holy sh-t. Lupkynis at the recommended full dose is priced at $142,200 per year!

Now, the company expects average net revenue per patient of $65K, after dose reductions and discounts, rebates, etc. But still, the full price is crazy high, could cause pushback

If this ends the day unchanged, I will be shocked and flustered..

New ALL time high, $18.61 just marked. Virus is still with us.

Better than nothing............

Wow

CCIV- I’m suspicious:

Churchill Capital IV Corp, formerly Churchill Capital Corp IV, is a blank check company. The Company is formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The Company is not engaged in any business operations and has generated no revenues.

Notice the name change, LOL?

Jess, Trading Cyclist posted over on Stocktwits that he didn’t own any shares of AUPH as he lost patience..

Aurinia- AUPH follow up from FDA approval on Friday:


Tom Silver
??@TomSilver39??


So $GSK acquired HGS(Benlysta= moderate efficiency)for $3.6B= $AUPH $30 Now, The Lupus Foundation said that lupus is blockbuster commercial opportunity. Even 25% of LN market= $2.5B, $AZN is also interested in Lupus. $AUPH M&A TP= ~$45 pic.twitter.com/jvmbWkiKWQ

1/23/21, 2:04 PM

Tom Silver
??@TomSilver39??


So $GSK acquired HGS(Benlysta= moderate efficiency)for $3.6B= $AUPH $30 Now, The Lupus Foundation said that lupus is blockbuster commercial opportunity. Even 25% of LN market= $2.5B, $AZN is also interested in Lupus. $AUPH M&A TP= ~$45 pic.twitter.com/jvmbWkiKWQ

1/23/21, 2:04 PM

GSK should sell the rights to their LN treatment, and purchase Aurinia. That would work..

For me, the absolutely scariest moment was in the dry eye trial, they picked patient comfort over efficacy. What were they thinking? That turned out to be a disaster as comfort was no difference, but, there was an improvement in efficacy. The market really punished them for that. In the end, fortunately, it didn’t matter, whew.

“I made a killing on ARIAD and a much bigger fortune on AURINIA. Thanks to all who kept the faith here. Where do we go from here? This gang needs to stick together. Glickman is a real hero. My mistakes in the past have mostly been due to choosing a stock with a poor CEO. “

Heldnova, same here. Ariad redefined the financial life of me, my family and close friends. And now, AUPH. I expect my faith and worship of God has a lot to do with it,

There was so much irony in your post that I had to comment. >>>”My mistakes in the past have mostly been due to choosing a stock with a poor CEO.”

We just got lucky with Ariad that Takeda bought them out. Dr Harvey Burger, CEO of Ariad was not very good. In fact he was on the list for consideration a number of times as the worst Biotech CEO of the year.

A tip of the hat to the real hero in this endeavor, CEO, Dr. Richard Glickman. For a historical perspective, Dr Glickman was a founding member of the company, and once Aurinia was steered to a successful path, left the company to enter retirement. However, when the company started to flounder, he was able to return and become the CEO once again, moving Aurina back on the path to approval, and then turning the company over to a new CEO, Peter Greenleaf. A footnote, Greenleaf was CEO for two other companies that were eventually sold. The last one was Scampo, which I also owned. Follow the Peter.

Thank you Dr Glickman for being a Grand Canadian!

Fluidigm Corporation (NASDAQ: FLDM) said it has received the CE-IVD mark for its Advanta Dx SARS-CoV-2 RT-PCR Assay, an extraction-free saliva-based test to detect nucleic acid from the SARS-CoV-2 virus. The CE-IVD mark is in conformance with the European Union in ivitro diagnostic directive.

The Advanta Dx SARS-CoV-2 RT-PCR Assay does not require collection via invasive nasopharyngeal swab, and the company's clinical studies for submission demonstrated 100 percent agreement between saliva results from the Advanta Dx Assay and results from paired nasopharyngeal samples tested with authorized assays.

The stock rallied 26.62% to $7.80 in after-hours trading.

Hydrogen to take 25% of all oil demand by 2050, Bank of America analyst says

https://www.cnbc.com/2021/01/22/hydrogen-will-take-25percent-of-oil-demand-by-2050-bank-of-america-analyst.html?__source=iosappshare%7Ccom.apple.UIKit.activity.CopyToPasteboard

Seems awfully optimistic as these articles usually are, but combined with renewables, the writing is on the wall for our oily world...

FDA Approves Aurinia Pharmaceuticals’ LUPKYNIS™ (voclosporin) for Adult Patients with Active Lupus Nephritis

https://ir.auriniapharma.com/press-releases/detail/210/fda-approves-aurinia-pharmaceuticals-lupkynis

This has been a very long hold for me...finally!

With the 2037 IP protection, Aurinia will not be independent for very long.. Everyone was waiting for the label..

Jess, your my best bud now on iHub..!

It is on Aurinia’s web site

Approved!!!!! Wow!! 2037 label!!!

You are welcome..

Earning beat is meaningless. I was hoping they had an opinion on approval chances..

We maybe hosed. Getting hammered..

I think a psychologist will be needed here..Jess

Links to upgrades??